Research and treatment news

This page updated on .

Longer articles are placed here.

Date: Wed, 04 Aug 1999 20:41:37 -0400
From: Midas Gold <>
Subject: Re: Nobody Likes Me, Everybody Hates Me...

More on worms, with an SCD-friendly twist at the end...
Wonderful worms
(New Scientist article)
Andy Coghlan

REGULAR DOSES OF WORMS might rid people of inflammatory bowel disease, say researchers in Iowa. They believe this distressing condition, which is increasingly common in the developed world, is caused by the absence of intestinal parasites. "We're living in sterile boxes, breathing sterile air and drinking sterile water," says Joel Weinstock, who led the research.

Weinstock and his colleagues at the University of Iowa have already fed six sufferers eggs that hatched and developed into parasitic worms. The results were so dramatic that they are planning a larger trial this autumn. Between the second and third week after treatment, five of the six patients went into complete remission," says Weinstock. A single dose of worms eased symptoms for about a month.

Inflammatory bowel disease--an umbrella term for ulcerative colitis and Crohn's disease--appears to be caused by an overactive immune system. Symptoms include diarrhoea, abdominal pain, bowel obstruction and bleeding.

Weinstock noticed that the rise in inflammatory bowel disease was preceded by a decline in intestinal worm infections. Seventy years ago, he says, 40 per cent of American children had worms such as Ascaris lumbricoides, which grow up to 20 centimetres long. As recently as the 1940s, many were infected with smaller whipworms (Trichuris trichuria). "By the 1960s, kids no longer had it," says Weinstock.

"The worms living in the gastrointestinal tract have been with us for 3 million years or longer," he says. "Our immune systems have grown used to their presence." And without such parasites, Weinstock believes the immune system is more likely to produce powerful inflammatory agents such as gamma-interferon, which fire up the activity of white blood cells called macrophages. "As we've de-wormed, people have developed immune systems which are not damped," he says.

The six patients in the initial trial were chosen because steroids and other drugs designed to dampen down the immune system had not helped. Working with his colleagues David Elliott and Robert Summers, Weinstock gave each patient a drink containing microscopic eggs of a species of intestinal worm that doesn't normally infect people. Although these worms can survive in the human gut, growing to about 1 centimetre, they cannot reproduce and are eliminated after a couple of months.

Balfour Sartor, an expert on inflammatory bowel disease at the University of North Carolina in Chapel Hill, is intrigued by Weinstock's experiment. "It's an appealing way of using something that's of fairly low toxicity to treat a set of diseases that for now we don't have a cure for," he says. Sartor is himself experimenting with Lactobacillus and Bifidobacterium gut bacteria, again with the idea that they may have dampening effects on the immune system.

However, there is still a long way to go before doses of worms or bacteria emerge as an accepted treatment for inflammatory bowel disease. Larger controlled trials are needed to show that the results obtained so far aren't merely due to the placebo effect.

- end of quoted article -


Date: Wed, 04 Aug 1999 19:31:49 -0400
From: Teresa Anderson-Little <>
Subject: SCD - good diet!

Protein-Rich Diets May Reduce Heart Disease Risk

(The Medical Tribune) - Contradicting the theory that high- protein diets may promote heart disease, researchers have found that a menu rich in animal and vegetable proteins may actually cut heart-disease risk.

Date: Mon, 27 July 1999
Loren Cordain's article "Cereal Grains: Humanity's Double Edged Sword" in World Review of Nutrition & Dietetics, 1999, no 84, page 19-73, and in the book 'Evolutionary Aspects of Nutrition and Health - Diet, Exercise, Genetics and Chronic Disease' is worth reading! A summary of the book can be found at this web page: The book is a compilation of articles showing how humanity's genetic makeup has been directly influenced by nutritional selective pressures and how our present day diet may be discordant with our stone age genome. The book is rather expensive and very technical and scientific in its language, but the description on the page is worth reading.

Date: Sun, 16 May 1999 16:05:32 GMT
Here's a roundup of what CCFA is featuring on their site,

* CLINICAL TRIAL ALERT: An ongoing clinical trial is enrolling patients to test an experimental drug as a treatment for Crohn's disease. The drug is called ISIS 2302. It is being developed by Isis Pharmaceuticals, a biotechnology company pioneering in a new area of drug discovery called antisense-technology. ISIS 2302 works through an antisense mechanism. This drug works at the genetic level to inhibit the production of proteins that plays a role in Crohn's, as well as other inflammatory diseases. That protein is called ICAM-1. More information can be found at:

* THE 1999 CCFA RESEARCH REPORT: A researcher once said that studying Crohn's disease and ulcerative colitis is "like looking for a needle in a haystack." Actually, it's more like looking for several needles, in haystacks of all shapes and sizes. But, we have made great strides in the past decade. A hypothesis is forming to explain inflammatory bowel disease (IBD). Check out this story at:
Visit the Weekly Features section at: to view all the parts of the research report. (Some parts have yet to be posted, but will be posted in the coming weeks).

From: "paulah" <>
To: "SCD" <>
Subject: Interesting IBD abstracts

Hi all,
I found these abstracts interesting and thought I might pass it along.

Date: Sat, 20 Mar 99 19:06:30 PST
From: Sarah Krein <>
Subject: Crohn's Disease on Increase

The results of a retrospective study of the incidence of paediatric IBD over an 11 year period have recently been made public.
The research taken at the University Hospital of Wales in Cardiff, revealed that the incidence of Crohn's disease more than doubled from 1.3 cases per 100,000 childhood population per year in the period 1983-1988, to 3.11 cases per 100,000 population per year in the year 1989-1993. In contrast, the incidence of UC remained the same throughout the study period at 0.71 per 100,000 per year. Results from an English study in 1983 showed similar trends.

These findings are in direct contract to figures published in mid-80s on children in Scandinavia. The annual incidence of crohns disease was only 2.5 per 100,000 per year, but the incidence of UC was much greater than 4.3 per 100,000 per year. In Norway and Sweden, the incidence of UC was greater than that of CD. The reasons for such a variation in the incidence of CD in some areas is unknown.

In 1993, the prevalence of CD in the childhood population of Wales was 16.6 per 100,000 and of UC, 3.42 per 100,000.

How interesting!


News Updates at the Crohn's & Colitis Foundation of America: "Progress in IBD - Under The Microscope"

Date: Mon, 15 Mar 1999 21:50:35 -0500
From: Tina Guarasci <>
Subject: searching journal articles

For those of you who are interested in searching through journal articles for the latest research being done on IBD and related issues, the following address allows you to search through Medline (a database of published articles) for free. Unfortunately, it doesn't include the entire article (although I think you can buy a copy from them), just the title, reference, authors and abstract.

Happy searching,

Date: Sun, Mar 7, 1999, 11:21:33
From: Diane Mathison
To: Mik Aidt
Subject: Re: RE: Infectious Microbes Under Suspicion

An interesting article recently describes Giardia as being "the only common primary infection causing chronic malabsorption", and "Giardia is perhaps the most common cause of chronic malabsorption in North America". It also says that a Giardia infection causes a "celiac-like syndrome".


Date: Thu, 4 Mar 1999 19:31:50 -0600
To: <>
Subject: Re: digestive diseases / bacteria (Off-Topic)

Dr. Mirkin, of the radio show, suggests treatment of Crohn's as though it were caused by bacteria, saying that the body would not be so stupid as to attack itself. Here's a link:
There are other links as well.


Date: Wed, 03 Mar 1999 15:23:02 +0100
From: Mik Aidt
Subject: Infectious Microbes Under Suspicion

On the front page of the International Herald Tribune, Tuesday, March 2, 1999, an article titled "Can a Person 'Catch' Heart Disease? Maybe -- Infectious Microbes Under Suspicion" states that a growing number of scientists believe that many illnesses long presumed to have roots in genes or lifestyle might be caused largely by infectious agents.
The article describes new research developments concerning heart disease, but the news, I think, could be interesting for people with other chronic diseases as well - like Crohn's or Ulcerative Colitis.
As stated in the article:
"That prospect is raising the intriguing possibility that people can "catch" kidney stones, cerebral palsy, Alzheimer's disease."
Some quotes from the article:
"Researchers announced last week that they had discovered a molecular mechanism by which mice can get heart disease from a bacterium.
And high-tech tests have been picking up previously undetectable bacterial "fingerprints" in people with other chronic conditions, strengthening the case that microbes are the hidden perpetrators.
The implications of the new theory are enormous, researchers say. Most important, it suggests that vaccines or antibiotics might have an unexpectedly big role to play in the treatment of chronic diseases that today are treated with only modest success through lifestyle changes, such as exercise and improved diet."
"The revolution began about five years ago, when definitive evidence arose that stomach ulcers are caused not by excess stomach acid, as had long been presumed, but by the bacterium Helicobacter Pylori. It was not easy persuading the scientific community to accept the new model.
Barry Marshall, an Australian scientist with a flair for theatrics, resorted to swallowing a beaker of the bacteria to help settle the question. Today, ulcers are treated primarily with antibiotics instead of acid-blocking drugs."

The full article can be found (this week only) on this webpage:


Date: Wed, 03 Mar 1999 07:29:03 -0800
Subject: Re: Infectious Microbes Under Suspicion

The press is finaly getting the message. Now if the medical bunch could just admit that they were wrong for a change.
Similar story in the Washington Post on March 1.

Date: Fri, 19 Feb 1999 12:00:57 -0500
From: "John Vazquez" <>
Subject: interesting website

This cousin of mine who is a veterinarian told me about this website that discusses the possible link between Crohns and the Mycobacterium Paratuberculosis.

Check it out it is very interesting.

Also, I have been on the diet for almost 7 months now and I appear to be in complete remission, I have no symptoms at all, and I have put on over 23 pounds, I actually have to start watching that I don't eat too much.

John Vazquez

Date: Thu, 4 Feb 1999 12:28:01 -0600 (CST)
From: Roy deCarvalho <>
Subject: News about new germ theory

News worth reading about germs (they are just realizing we were right):


Date: Fri, 29 Jan 1999 19:59:50 +0100
From: (mik aidt)
Subject: Fiber, Sugar and the Risk of Colorectal Cancer

Hi everyone in the group,

I came across an article, "Dietary Fiber and the Risk of Colorectal Cancer and Adenoma in Women", in the last issue of The New England Journal of Medicine (January 21, 1999, Volume 340, Number 3) which I find interesting in regard to Gottshall's and Lutz's findings of the many negative effects sugar has on our bodies.

This is a quote from the editorial of the issue which is entitled "Fiber and Colorectal Cancer -- Where to Now?": "Is it really a surfeit of sugar, not an absence of fiber, that causes the risk of colorectal cancer to increase? Somewhat ignored, sugar consumption is consistently associated with the risk of colorectal cancer, and in a dose-response fashion. Perhaps a high intake of calories, aberrant responses to carbohydrates, and a lack of physical activity are also relevant."

This being said in regard to cancer, not to colitis. However, concerning sugar as well as physical activity, these new findings are - as far as I can see - confirming why we SCD'ers are on the right track.

In Denmark, results of another survey were published recently, stating that scientists now have evidence that four hours of exercise a week (approx. half an hour a day) has a significant effect on the healing process for patients with colon cancer.

The New England Journal of Medicine article summary and editoral can be found at:


Date: Wed, 11 Nov 1998 09:39:46 -0500
From: "Serge, Luba" <>
Subject: JAMA & alternative medicine

Some interesting articles from the JAMA (The Journal of the American Medical Association) on alternative medicine. What do you think, is this a sincere interest in alternatives or are they realising that they are loosing their prestige and missing out on lucrative practices?

(mother of Lara, CD)

Date: Mon, 02 Nov 1998 00:48:31 +1000
From: Phillips <>
Subject: Re: Entecort off-topic wrote:

> I have been surfing the net trying to find more information on Entecort made
> by Astra also known as budesonide.Claudette had mentioned she might have some
> info. I am very interested and will be willing to go to any lengths to get it
> (even take Chanelle to Canada to a Dr. there as it is not available in the
> U.S.) We are on our third attempt to get her off prednisone and God willing we
> will succeed time but if not we have to find a safer alternative because of
> the long term side effects of the pred. Any leads will be greatly appreciated
> Jill UC

Did you see the posting on "Infliximab"?? It's something new that just got
approved in the states. It's what I'm trying to get my doctor to prescribe to
me. I don't like the side effects of prednisone and the Pentasa is not doing
everything I need it to do. Infliximab (also known as Remicade) has only a few
side effects, IF you get any side effects at all, and it's an injection....not
like a continuous pill taking escapade that I endure now. It is a combination of
human and mouse (watch out for those unusual cravings for cheese and unexplainably
sudden fear of cats (I'm kidding!!)), antibodies that bind to something in your
body that causes the inflammation. It doesn't supress your immune system...which
was the next thing on my list to try (immunosupressants). I'm not sure what the
web page address is, but if you use a search engine and look up "Infliximab" or
"Remicade" it should turn up something. The other is a little
expensive, but no more I suppose then all the pills....hope it helps.

Peace & Protect....

Date: Thu, 08 Oct 1998 07:16:29 -0800
From: "Ben Montag" <>
Subject: Research

I was just reading the CCFA site. There is an article that Bayer Corp. is
initiating a study of Ciproflaxin (an antibiotic) for treating Ulcerative
Colitis. The signifigance to us is the study is prompted by the conclusion
that "a number of intestinal pathogens (e.g., bacteria) are associated with
relapses of ulcerative colitis, and may act as triggering factors."
Though this is not the direction we would like to see research go, this does
give us all ammunition when we are in discussions with skeptical
gastroenterologists that there is a bacterial cause to our disease.

Fra: Crohn's & Colitis Foundation of America
Dato: 28. august 1998 20:31

Greetings from CCFA! Here's an update of recent stories and new sections
you'll find on our Web site, at :


** As you may know, our big story this week was the approval of
Remicade+, a new drug for Crohn's disease. You can find the story at

** Speaking of Crohn's, there have also been some new findings on the
drug budesonide:

** Here's a topic we're all interested in: the intimate relationship of
sex and IBD. Look out, Dr. Ruth!

Date: Thu, 08 Oct 1998 14:58:27 -0800
From: "Ben Montag" <>
Subject: chat-medical references

The best medical overview of Crohn's disease and Ulcerative Colitis I have
found is Crohn's Disease and Ulcerative Colitis by Dr. Fred Saibil. It is an
excellent reference of what the diseases are and what treatments are
available. However, he does not deal with the SCD diet or alternative
medicines at all. The book can be bought at There are also
plenty of reviews there to judge for yourself.

Date: Sat, 03 Oct 1998 12:28:22
From: T G <>
Subject: Diet and Chrohn's article

I thought some people might be interested in a recent review article that
I've found. So far I have only read the abstract, but I will be getting
the article to read soon.
The reference is: Nutritional therapy in Crohn's disease.
Inflamm Bowel Dis. 1998 Feb;4(1):45-53. Review.

Here is a copy of the abstract:
"The value of nutritional support in the prevention and treatment of
malnutrition in Crohn's disease is undisputed but its role in
primary therapy continues to be debated. Controlled trials have
demonstrated that enteral nutrition induces remission rates
comparable to that of corticosteroid therapy in Crohn's disease and remains
the treatment of choice for specific subgroups such
as children with signs of growth impairment and patients with intolerable
steroid-induced side effects. The mechanism by which
an enteral diet induces remission in Crohn's disease is unclear. Bowel
rest, reduced antigenic load, nutritional effects, the
provision of trophic amino acids, modification of gut flora, intestinal
permeability, or fecal pH have been proposed. Equally, the
fat profile of the feed may reduce pro-inflammatory ecosanoid synthesis and
thus modify disease activity. Maintaining long-term
remission remains a challenge in the management of this disease. Cyclic
administration of enteral diets, maintenance drug
therapy, fat manipulated formulas, or fish oil therapy may be strategies to
prolong diet-induced remission. In the future, nutrient
derivatives that play a role in the protective processes of the intestinal
mucosa may have application in nutritional therapy in
Crohn's disease. "

Take care,

Date: Mon, 05 Oct 1998 09:29:36 -0400
From: T G <>
Subject: enteral/parenteral

I will try to clear up the issue of what exactly the people in the study on
diet and Crohn's were eating when I get my hands on the actutal article.
Unfortunately, the library at the University here does not carry it, so I
will have to do some looking around.
The thing I found most significant about the abstract was the statement
that these type of diets might work because of their effect on gut flora.
Since this is what we are doing with our diet, I thought it was important
that a study out there actually recognized that fact.

Take care,

Date: Thu, 1 Oct 1998 11:00:11 -0700
From: "Benke, Anna" <>
To: "Ibdlist (E-mail)" <>, "SCD (E-mail)"
Subject: Scientists isolate immune system 'on/off switch'

07:42 AM ET 09/29/98
Scientists isolate immune system 'on/off switch'

By Jonathan Birt LONDON, Sept 29 (Reuters) - Scientists have isolated a
which they believe acts as an on/off switch for the body's
immune system, promising new ways of treating conditions ranging
from cancer to Crohn's Disease, the British company behind the
breakthrough said on Tuesday.
Researchers at the U.S. arm of Chiroscience Group Plc are
also close to locating a second gene which could reverse bone
wasting caused by osteoporosis, a condition which affects
millions of people over 60 and leads to more than one million
fractures in the U.S. every year.
Research and Development Director Robert Jackson said
uncovering the gene which regulates the body's immune response
could one day lead to development of a whole new range of drugs.
''Sometimes you want to turn it off and sometimes you want to
turn it on,'' Jackson told Reuters.
Turning the immune system on or up could help in conditions
like AIDS and cancer, where the body's efforts to fight off
tumours are currently too weak.
''If we could strengthen that, we could develop drugs to
help the body react to tumours,'' Jackson said.
But switching it off or down might be useful in a range of
diseases caused by an overly fierce immune response -- such as
rheumatoid arthritis, diabetes, psoriasis, Crohn's Disease,
ulcerative colitis and allergy.
Gene-based research at the former Darwin Molecular
in Seattle, Washington, which Chiroscience bought in 1996, is
also close to locating a mutant gene which may offer a way of
reversing the effects of osteoporosis for the first time.
Scientists are studying around 100 people and their
in South Africa with extremely strong bones caused by a mutant
gene which causes bone density to increase as people age -- the
exact opposite of osteoporosis.
''We are close to identifying a unique bone structure gene
for osteoporosis,'' Chief Executive Officer John Padfield told
''All other treatments try to stop bone loss getting
What our gene appears to do is increase bone density very
substantially -- if this turns out to be true when we test a
drug, that would be a revolutionary treatment for
The company announced the discoveries as part of a
update on its research and development activities. Shares in
Chiroscience were up seven percent or 17 1/2 pence in early
afternoon trading in London.
Chiroscience said it will also work with the small British
genome company Gemini Research, which has built up a database of
genetic information based on identical twins. The two companies
are to look for mutant genes linked to obesity.

Date: Mon, 24 Aug 1998 17:48:06 -0500
From: "Bixler, Cindy" <>
To: "''" <>
Subject: RE: Infliximab

> -----Original Message-----
> From: macneil []
> Sent: Monday, August 24, 1998 4:36 PM
> To:
> Subject: infliximab
> On our news today there was an item re a new drug called Infliximab which
> just received FDA approval in the US for the treatment of Crohn's.
> Apparently it is a radical new treatment as it neutralizes an antibody
> which
> attacks the protein involved in Crohn's.
> If anyone comes across info regarding it could you send it to me?
> I'm in Canada so info on it is scarce so far.
> -I wonder if it also helps UC.
> Thanks-Cathy

Here is the article...

Crohn's Disease Drug Approved
About 400,000 Americans have Crohn's disease, a severe gastrointestinal
tract inflammation that causes diarrhea, abdominal pain, fever and
weight loss.
The Associated Press
W A S H I N G T O N, Aug. 24 - The Food and Drug Administration today
approved a revolutionary treatment for the debilitating bowel disorder
Crohn's disease: A biologically engineered antibody that attacks a
protein responsible for much of patients' misery.
Centocor Inc.'s infliximab is a part-human, part-mouse antibody, to be
sold under the brand name Remicade.
About 400,000 Americans have Crohn's disease, a severe gastrointestinal
tract inflammation that causes diarrhea, abdominal pain, fever and
weight loss. In severe cases, patients develop intestinal blockages and
ulcer-like channels called fistulas that burrow through the bowel wall.
It mostly strikes women, usually between ages 20 and 35. There is no
cure. Most patients are treated with steroids to reduce the
inflammation; some require repeat surgeries to remove damaged parts of
the intestine.
Remicade is a monoclonal antibody, a biologically engineered drug that
sweeps through the body hunting down and neutralizing tumor necrosis
factor, a protein that causes much of the intestinal inflammation.
In a study of 108 moderate to severe Crohn's patients, 82 percent who
received an injection of Remicade improved, including 48 percent who
went into remission. That compares with 16 percent of patients who
improved while taking a placebo.
Heals Fistula Sores
In the worst-case patients, Centocor says Remicade is the first medicine
documented to heal open fistulas: 68 percent had at least half of their
ulcer-like sores close during therapy, vs. 26 percent of patients who
received dummy injections.
But the benefits wear off: patients benefited most within the two to
four weeks after a single dose, the government said, and the percentage
of patients who saw benefits then fell over the next few months.
As part of the drug's approval, Centocor agreed to study whether the
drug also works over a longer time period, and whether it is safe for
long-term use, the government said.
Side effects included hives, shortness of breath or reduction of blood
pressure during the drug's infusion. Patients also may suffer nausea,
fatigue and infection, the company warned.
Centocor says pharmacies should have supplies of Remicade in early
October. A price was not immediately announced. Patients may also know
the drug as Avakine, the name Centocor first used when testing it.

Date: Tue, 11 Aug 1998 13:45:17 -0400
From: "Serge, Luba" <>
Subject: OFF TOPIC (UK - milk and Crohn's disease)

The link between milk, mycobacterium paratuberculosis & Crohn's disease
seems to be hitting the news in the UK today. Just a bit came over the
radio here but the BBC seems to have good coverage. Thought it might be of


Date: Sun, 02 Aug 1998 13:09:12 PDT
Date: Mon, 10 Aug 1998 12:02:58 -0400
From: Midas Gold <>
Subject: A Gut Feeling

For anyone who's interested, here is an IBD/gut bacteria thesis that
draws strikingly different dietary conclusions than does Elaine
Gottschall in _Breaking the Vicious Cycle_.

(Also placed here)

Date: Sun, 2 Aug 1998 13:09:12 PDT
From: C Smith <csmithz@HOTMAIL.COM>
Subject: News about ISIS Drug trial

This was released by ISIS pharmaceuticals on June 10, 1998
via the PR Newswires (actually for stock holders)


Isis Crohn's Disease Drug Shows Evidence of Durable Remission,
Steroid-Sparing And Fistula Healing Effects

Results of Phase II Trial Show Inhibition of ICAM-1 and Other
Inflammatory Markers,
Supporting Antisense Mechanism

CARLSBAD, Calif., June 10 /PRNewswire/ -- In the June 1998 issue of
Gastroenterology, Isis Pharmaceuticals (Nasdaq:
ISIP - news) and Crohn's disease academic researchers report on the
results of a well-controlled 20-patient Phase II trial of
ISIS 2302 in the treatment of Crohn's disease. These results show a
statistically significant lowering of steroid requirements
(p=0.0001) in ISIS 2302-treated patients, and show that by the end of
the one month treatment period, ISIS 2302 produced
disease remission (Crohn's Disease Activity Index <150) in 47% of
patients treated with the drug. The mean duration of
remission was prolonged; at the end of the 6-month trial, 5 of the 7
ISIS 2302-treated remitters were still in remission following
a single course of treatment. In addition, at the end of 6 months,
corticosteroid treatment was completely discontinued in 33%
(5 of 15) of the ISIS 2302 treated patients and in no placebo patients.
Long-term steroid use can cause severe side effects
including osteoporosis, immune suppression and endocrinological changes.

This publication includes data on the 20-patient, double-blinded,
placebo- controlled, randomized (3:1; ISIS 2302: placebo)
Phase II trial which were previously presented at two scientific
conferences, as well as data supporting that ISIS 2302 is
working through an antisense mechanism.

The publication is entitled, ''A Placebo-Controlled Trial of an ICAM-1
Antisense Oligonucleotide in the Treatment of Crohn's
Disease.'' The authors are Bruce R. Yacyshyn, M.D., Mary Beth
Bowen-Yacyshyn, Ph.D., Lawrence Jewell, M.D., of the
Department of Gastroenterology, University of Alberta, Edmonton; Joseph
A. Tami, Pharm.D., C. Frank Bennett, Ph.D.,
Daniel L. Kisner, M.D., and William R. Shanahan, Jr., M.D., of Isis

ISIS 2302 is an antisense inhibitor of intercellular adhesion molecule
-1 (ICAM-1), a cell adhesion molecule implicated in a
wide range of inflammatory diseases and conditions. The drug is a key
asset in the cell adhesion collaboration between Isis and
Boehringer Ingelheim GmbH. A 300-patient pivotal quality trial of ISIS
2302 in patients with steroid- dependent Crohn's
disease is underway in North America and Europe.

Fistulae Healing

Two patients who had an open fistula when they entered the study and
were treated with ISIS 2302 experienced healing of
their fistula. Fistulae are open channels from the bowel to the skin and
other organs through which fecal matter can drain,
causing soiling, pain and infection. In addition, both patients in this
study with gastroduodenal Crohn's disease (located where
the stomach meets the intestine) were treated with ISIS 2302, and both
experienced resolution of upper gastrointestinal
obstructive symptoms during the course of treatment. These two patients
remain free of their obstructive symptoms after over
one year following treatment with ISIS 2302.

''The ability of ISIS 2302 to produce durable remissions in patients
with steroid-dependent Crohn's disease, to heal fistulae
and to reduce and, in many patients, eliminate steroid use, strongly
suggests that ISIS 2302 can be an important treatment for
Crohn's disease,'' said Bruce R. Yacyshyn, M.D., Division of
Gastroenterology, University of Alberta, Edmonton, and lead
author on the paper.

Antisense Mechanism Supported

Newly released findings reported in the Gastroenterology article suggest
a strong correlation between treatment with ISIS
2302, reduction in ICAM-1 expression in affected bowel tissue and
apparent release of proinflammatory lymphocytes from the
gut. In the intestinal mucosa of patients treated with ISIS 2302,
decreases in ICAM-1 expression (CD54) were seen in
significantly more of the ISIS 2302-treated patients than
placebo-treated patients, and higher doses of ISIS 2302 produced
greater effects. In addition, an increase in peripheral blood T-cells
bearing the adhesion molecules alpha-d and beta-7, which
are involved in lymphocyte homing to the intestine, was observed. The
correlation of ICAM-1 inhibition and the apparent
release of immune cells from the intestine suggest that suppression of
ICAM-1 results in an interruption of the immune cell
intestinal trafficking and retention that are critical to the
perpetuation of the inflammatory disease process. This interruption may
allow restoration of normal bowel mucosal integrity and immune function,
thereby resulting in prolonged disease suppression.

''In patients treated with ISIS 2302, the changes observed in peripheral
blood lymphocyte and intestinal mucosal expression of
adhesion molecules strongly suggest a therapeutic effect with ISIS 2302
achieved through an antisense mechanism of action.
These data provide the first evidence of an interplay in inflammatory
disease between specific cell adhesion molecules, with
potential implications for designing antiinflammatory drugs in the
future,'' said Dr. Yacyshyn.

This press release contains forward-looking statements concerning the
therapeutic potential of ISIS 2302, an antisense drug in
development for Crohn's disease and other inflammatory disorders. Such
statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics. Actual results could differ
materially from those projected in this release. As a result,
the reader is cautioned not to rely on these forward-looking statements.
These and other risks concerning the therapeutic
potential of ISIS 2302 are described in additional detail in Isis'
Annual Report on Form 10-K for the year ended December
31, 1997 and in the company's most recent quarterly report on Form 10-Q,
which are on file with the U.S. Securities
Exchange Commission, copies of which are available from the company.

Isis Pharmaceuticals, based in northern San Diego County, is engaged in
the discovery and development of novel human
therapeutic compounds. Isis has six compounds in human clinical trials:
fomivirsen, to treat CMV-induced retinitis in AIDS
patients, has completed Phase III clinical trials and an NDA has been
filed; ISIS 2302, an inhibitor of ICAM-1, is in a pivotal
quality trial for Crohn's disease, Phase II clinical trials for renal
transplant rejection, rheumatoid arthritis and ulcerative colitis,
and is being explored as a topical administration for psoriasis and an
aerosol administration for asthma; ISIS 3521/CGP
64128A is in Phase II trials as a treatment for cancer; ISIS
5132/CGP69846A is in Phase II clinical trials as a treatment for
cancer; ISIS 2503 is in Phase I trials as a treatment for cancer; and
ISIS 13312 is in Phase I/II clinical trials for the treatment of
CMV retinitis in AIDS patients. The company also has several additional
compounds in preclinical development. Isis' broad
medicinal chemistry and biology research programs support efforts in
both antisense and combinatorial drug discovery.


2292 Faraday Avenue
Carlsbad, CA 92008
(760) 931-9200

Does anyone know about the current trial that ISIS
is conducting?

It's up to the FDA to approve it and from the
Yahoo stock board ( and the stock
ticker (ISIP) I found messages claiming FDA
approval is due October this month....?

Can someone please check with FDA ? This drug
could change lives

C Smith <csmithz@HOTMAIL.COM>

Date: Sat, 18 Jul 1998 14:03:51 -0400
From: "Claudette Cameron" <>
To: <>
Subject: re Entocort

Hello everybody;
Just thought I would let you know that I have found some information re the
drug Entocort.It is a new drug specifically for Chron sufferers which has
been recently approved by Health Canada.If you are interested in finding
out more, go to
My grandson has recently been removed from prednisone and has started the
Entocort.......... Claudette

Date: Thu, 16 Jul 1998 12:59:49 -0400
From: Midas Gold <>
Subject: Mycobacterium Paratuberculosis, CD, and Pasteurized Milk

Anti-Milk Group Exposes Claim That Normal Pasteurization Kills
Dangerous Bacterium in Milk

Tuesday, July 14 9:07 AM ET

AntiDairy Coalition Faults FDA and USDA for Misinterpreting Scientific

NEW YORK (BUSINESS WIRE) - The AntiDairy Coalition has denounced a
claim, based on a recent U.S. Department of Agriculture (USDA) study,
that normal pasteurization practiced by dairy producers nationwide
inactivates a dangerous bacterium routinely found in raw milk.

In his weekly AntiDairy Coalition Newsletter column on the Internet,
Coalition executive director Robert Cohen says the USDA study, which
was reported in the May 10, 1998 issue of Hoard's Dairyman, a trade
publication, has been completely misrepresented by the agency and by
the Food and Drug Administration (FDA) in claiming that normal
pasteurization (72 degrees centigrade for 15 seconds) destroys
mycobacterium paratuberculosis, the bacterium linked to Johne's
disease in cows and Crohn's disease in humans that produces persistent
and severe diarrhea.

Cohen, author of "Milk - the Deadly Poison," says that the USDA study
actually revealed that the dangerous bacteria were not totally
inactivated until after 15 minutes of pasteurization at 72 degrees

That's "very bad news for all milk drinkers," says Cohen. "Normal
pasteurization at this temperature calls for only a 15-second
treatment, not 15 minutes. We believe the government and Hoard's
Dairyman are misleading the public into thinking pasteurized milk is
safe from mycobacterium paratuberculosis when the USDA's own scientist
is saying that pasteurization inactivates the bacterium only when the
process maintains at least 72 degrees centigrade for at least 15
minutes. That's 14 minutes and 45 seconds longer than the normal
commercial pasteurization of milk in the United States."

The USDA study is entitled "Heat Inactivation of Mycobacterium
paratuberculosis in Raw Milk: Are Current Pasteurization Conditions
Effective?" Based on this study, Hoard's Dairyman told its
100,000-plus milk producer subscribers, "Heat treatment
(pasteurization) destroys this dangerous disease."

Cohen says the FDA supports the same conclusion. He refers to a letter
addressed to government officials from Joseph Smucker, team leader of
the Milk and Safety Team at the Center for Food Safety and Applied
Nutrition, a branch of the FDA. The letter says: "After a review of
the available literature on the subject, it is the position of FDA
that the latest research shows conclusively that commercial
pasteurization does indeed eliminate this hazard."

Cohen says every assertion about pasteurization's effectiveness is
refuted in the abstract of the USDA study, which states: "Currently,
it is not known whether commercial pasteurization effectively kills
mycobacterium paratuberculosis in contaminated raw milk."

"This sentence," Cohen says, "contradicts every conclusion made from
this very same paper!"

The senior author of the abstract is Judy Stabel, Ph.D. On the second
page of Dr. Stabel's paper (published in the December 1997 issue of
Applied and Environmental Microbiology), she reveals: "Bacteria were
not totally inactivated until after 15 minutes of incubation
(pasteurization) at 72 degrees centigrade."

In her paper, Dr. Stabel also writes: "There is no definitive evidence
to date that viable M. paratuberculosis is present in retail
pasteurized dairy products."

When she was asked why there was no evidence and if milk samples had
ever been tested at retail sites, Cohen says her response was "No."
When asked "Why not?" she replied, "I don't know."

However, Cohen contends that British scientists have taken milk
samples at the point of retail purchase and have cultured live
tuberculosis bacteria from these samples.

Cohen concludes that the FDA and USDA have misinterpreted Dr. Stabel's
paper, and scientific evidence suggests that this dangerous bacterium
survives pasteurization. "This is just another example of how
Americans are being betrayed by regulatory agencies like FDA and
USDA," Cohen warns.

Formed in June 1998, the AntiDairy Coalition includes some of the
country's top physicians and health educators: Dr. Julian Whitaker,
author and editor of the monthly newsletter, Health & Healing; Dr.
Charles Attwood, often called heir apparent to Dr. Benjamin Spock; Dr.
Vicki Griffin; Dr. Daniel Twogood; Dr. Richard DeAndrea and Dr.
Richard Schwartz.

This release is available on the KCSA Public Relations website at

Contact: KCSA Worldwide, New York Jennifer Urezzio, 212/896-1223

Date: Tue, 14 Jul 1998 10:06:49 -0700
From: David Hyde <dhyde@CCSF.CC.CA.US>
Subject: diet linked to colon cancer

Monday July 13 6:23 PM EDT

Western diet linked to colon cancer risk

NEW YORK, Jul 13 (Reuters) -- Diets rich in meat and low in fruits and
vegetables may increase the risk of colon cancer,
concludes a report.

"The dietary pattern associated with the greatest increase in risk is
the one which typifies a Western-style diet," say researchers
led by Dr. Martha Slattery of the University of Utah Medical Center in
Salt Lake City.

According to the American Cancer Society, colon cancer kills over 46,000
people every year in the United States, making it
the country's second leading cause of cancer death, after lung cancer.
Experts have long speculated that certain foods and diets
may influence colon cancer risk.

In their study, published in the current issue of the American Journal
of Epidemiology, the investigators used detailed
questionnaires to ascertain the long-term eating patterns of nearly
4,400 American adults. Half of those interviewed were colon
cancer patients, while the other half were healthy "controls."

Men and women who ate what the researchers labeled a "Western" diet --
high in red and processed meats, refined grains and
sugars, and low in fresh fruits and vegetables -- doubled their overall
risk for colon cancer. This type of diet was also strongly
associated with higher daily cholesterol and energy intake, weight gain,
and obesity.

In contrast, individuals who stuck to what the researchers labeled a
"prudent" diet -- low in red meat and sugars but high in
fish, poultry, fresh fruits and vegetables -- achieved a nearly 40%
reduction in their colon cancer risk. These individuals also
exercised more and had an average lower body weight than those on more
"Western" diets.

A third type of diet, where individuals substituted whole grains for
processed grains, poultry for red meat, and margarine for
butter, provided about a 15% reduction in risk, but statistical analysis
shows that this difference may have occurred by chance.
The researchers point out that these 'substituters,' "while adopting
many healthy eating patterns, did not include vegetables as
part of their dietary pattern and (therefore) did not experience the
reduced risk of colon cancer observed in those with the
prudent diet."

Slattery and her colleagues believe the study "lends further support to
the commonly held belief that a Western-style diet
contributes to colon cancer risk and that a prudent diet, one enriched
with vegetables, refined grains, fruits, fish, and poultry,
may help prevent colon cancer." SOURCE: American Journal of Epidemiology

David Hyde

Office of Research and Planning
City College of San Francisco
50 Phelan Ave.
Rm. E203
San Francisco, CA 94112
Phone: 415.239.3227
Fax: 415.239.3010

In Infection and Immunity's (published by American Society for Microbiology) November issue, Vol. 65, No. 11, 1997, page 4476-4482, you can read an article about some of the latest findings concerning the "V antigen" - a protein which can turn out to be a powerful weapon against infectious diseases like Crohns and Colitis.
The article is entitled: " Regions of Yersinia pestis V Antigen That Contribute to Protection against Plague - Identified by Passive and Active Immunization" and the research was carried out in England by Jim Hill, Sophie E. C. Leary, Kate F. Griffin, E. Diane Williamson, and Richard W. Titball at the Microbiology departmanet at CBD Porton Down in Salisbury, Wiltshire SP4 OJQ. 

At St. Bartholomew's Hospital in England, the V antigen is presently being tested on Colitis patients.

In November 1997, over 2,500 gastroenterologists gathered in Chicago for the American College of Gastroenterology's 62nd Annual Scientific Meeting to discuss the latest scientific advances in GI research, treatment of digestive diseases and clinical practice management. Read the introductory paper her:

Some of the headlines were:
  • Gene-Based Therapy Offers Potential Breakthrough in Treating Inflammatory Bowel Disease, a multi-center study indicating promising early results for an experimental genetic treatment for Crohn's disease, which affects over 2 million people in the United States.

  • Primary Sclerosing Cholangitis Increases the Risk of Colorectal Cancer in Ulcerative Colitis Patients, reports on a study by Kirti Shetty, MD, found that patients with ulcerative colitis, a form of inflammatory bowel disease, who also suffer from a liver disease known as primary sclerosing cholangitis have a significantly higher risk of developing fatal colorectal cancer.

  • Evidence Against Zoonotic Transmission of H. pylori from Domestic Felines, a poster supported by an ACG Research Grant that found that cats are not a carrier of H. pylori, the bacteria that causes ulcers, and therefore do not transmit the bacteria to humans.

  • Characteristics of African American and Caucasian Patients with Inflammatory Bowel Disease (IBD), research led by Jeffrie Kamean, MD provides data dispelling the common misperception that there are differences between African American and Caucasian IBD patients.

  • Surfing the Net May Be Hazardous to Your Health: Quality of GI Information on the Internet, a study led by J.F. Barry O'Conner, MD that evaluated the origin, nature, and validity of information and treatment recommendations found on the internet for four major GI diseases. The study found that ten percent of Internet sites offering treatment advice posted remedies that are of no proven benefit.

Article on Enzyme Potentiated Desensitization.
Lists Crohns and other IBD/IBS diseases as being something that has been successfully treated with Enzyme Potentiated Desensitization.

Date: Wed, 26 Nov 1997 11:39:28 +0000
From: Keith Monroe <keith.monroe@MCMAIL.COM>
Subject: Dysbiosis article

I now have an electronic version of the article on intestinal dysbiosis and I have permission to distribute it to people on this group. If anybody would like a copy, please send me an email. I could post the whole thing, but it's about seven pages long so I wouldn't want to waste space if only a few people are interested.

Here's an introduction to the article:

"With the advent of biochemical and microbial stool analysis panels, an increasing number of physicians are seeking a clearer understanding of the relationship between the ecology of the digestive tract and local and systemic factors affecting health and disease. It can be described as being due to either putrefaction, fermentation, deficiency, or sensitization. A number of inflammatory diseases within the bowel or involving skin and connective tissue have been reported in association with dysbiosis. This article details the relationships, causes, and treatment options for dysbiotic-related conditions."


4 August 1997

=====================MEDSCAPE's MedPulse(R)===================
MedPulse is Medscape's email newsletter informing registered members of new content posted on the world's leading medical Web site.

  • Mycobacteria and Crohn's Disease
  • -------------------------------------------------------------
    Crohn's disease has features in common with Johne's disease, an intestinal infection of animals caused by Mycobacterium paratuberculosis. Molecular biologic techniques have been used to find a link between Crohn's disease and mycobacteria, but these studies have yielded conflicting results so far.
    [Infect Med 14(7):569-573, 1997]


    Link to article may be found at:

    Date: Fri, 25 Jul 1997 18:22:45 -0700
    From: Dempsey <stellar1@PACBELL.NET>

    Subject: Bowel Disease and Diet

    Here is an excellant article on reactive bowel disease and diet. There are a few references in it that back up Elaine's hypothesis for the elimination of dairy and cereal grains. For example:

    "In a study by V. Alum Jones et al, 67% of patients with IBS improved after one week on a strict diet. The GIT disturbance was related to increased levels of Prostaglandin E2 and not related to IgE-mediated hypersensitivity. Nanda et al implicated dairy products and cereal grains in IBS; almost half of the 200 patients were treated with diet revision, and almost half improved. Pagenelli showed similar improvement on a restricted diet and increased GIT permeability to beta-lactoglobulin was demonstrated in 3 patients using serum measurements with a sensitive immunoradiometric assay after milk challenge. Circulating immune complexes after challenge with milk were demonstrated in 9 of 13 patients before diet revision. The addition of cromolyn sodium ( Nalcrom), a mast-cell stabilizing agent, improved symptom remission in some patients."


    Mon, 7 Jul 1997 9:34:03 GMT

    Hi everyone,

    I found an article on "Current Medical Therapy for Inflamatory Bowel
    Disease" on the net lately
    (Full text under:

    Especially the part on "Short-Chain Fatty Acids" (see below) aroused my
    interest. Does anyone of you know a brand name of such a medicament?
    Pharmacists and doctors here haven`t heard of it at all.


    "Short-Chain Fatty Acids

    Short-chain fatty acids (SCFA), especially butyrate, are the preferred
    energy substrate for distal colonic epithelial cells. Decreased fecal
    concentrations of SCFA have been shown to occur in patients with
    ulcerative colitis but not Crohn's colitis. Table 3 summarizes clinical
    studies on the use of SCFA enemas for active distal ulcerative colitis.
    The clinical response rates of 56% to 90% are slightly lower than those
    reported for hydrocortison or mesalamine enemas. The uniqueness of SCFA
    therapy is that the presumed mechanism of action is feeding the colon
    rather than altering its immune response. SCFA therapy given
    concurrently with other agents might offer even more promise. In fact,
    one small uncontrolled trial reported a 100% response rate using a
    combination SCFA/5-ASA enema therapy in patients with previously
    refractory distal ulcerative colitis."

    Re: Question
    Tue, 8 Jul 1997 0:07:32 GMT

    Hi, Miroslav. I've been trying to find out about this, too, without much
    success (haven't had too much time). I also came across a paper that said
    they were studying aloe vera for SFA's. SFA's (like butyric acid) are also
    produced in a normally-functioning bowel from enzymes working on fibre.

    D. Hartl RMT

    Re: MedLine Search confirms link between High Carbohydrate In...
    Sat, 12 Jul 1997 11:09:50 GMT

    I would like to make a supplement to this:
    >In a recent IBDlist digest, someone mentioned the free MedLine link at
    >the National Institute of Health's National Library of Medicine, at

    I am using Medline as often as possible and did find another interesting article recently:

    Martini & Brendes:
    Increased Consumption of Refined Crabohydrates in Patients with CD.

    Klin. Wschr. 54, 367-371 1976.

    Conclutions from reading:

    There was an significant difference in intake of refined suger between 63
    patients and a control group of 63: 482 gram/week against 285 gram/week.
    Before the disease was recognized the patients consumed even greater amount:
    742 gram/week!!

    Martini and Brandes suggests that: "It is possible that the increased
    consumtion of suger for many years may lead lead to changes in the
    intestinal bacterial flora and general milieu in such a way that the mucosa
    may be damaged..."

    This trial from 1976 (!) has certainly been IGNORED by school medicine.

    Odd Oivind Bergstad

    MedLine Search confirms link between High Carbohydrate Intake and IBD
    Fri, 11 Jul 1997 18:36:36 GMT

    In a recent IBDlist digest, someone mentioned the free MedLine link at the National Institute of Health's National Library of Medicine, at
    I followed the link to MedLine and did a search there on Carbohydrate and Diet and IBD. I found the following:

    Eur J Gastroenterol Hepatol 7 (1): 47-51 (Jan 1995)

    Dietary habits as risk factors for inflammatory bowel disease.

    by Tragnone A, Valpiani D, Miglio F, Elmi G, Bazzocchi G, Pipitone E, Lanfranchi GA

    Division of Internal Medicine, Bellaria Hospital, University of Bologna, Italy.

    OBJECTIVE: To examine the influence of dietary factors in Italian patients with ulcerative colitis and Crohn's disease.
    DESIGN: We studied dietary habits immediately prior to the onset of disease in 104 patients enrolled in a prospective, epidemiological study of the incidence of inflammatory bowel disease in Italy.
    METHODS: Each patient was interviewed using a recall questionnaire to provide information on the daily intake of nutrients. The differences in diet between patients and healthy subjects matched for age, sex and city of residence were determined.
    RESULTS: Our data confirm that patients with Crohn's disease and ulcerative colitis have a high intake of total carbohydrate, starch and refined sugar. This resulted in a significantly higher relative risk (P < 0.001) in both ulcerative colitis and Crohn's disease patients. Total protein intake was significantly higher in ulcerative colitis, but not in Crohn's disease patients, than in controls. Fibre consumption did not differ between patients and controls.
    CONCLUSIONS: Our results confirm that carbohydrate consumption is significantly higher in IBD patients than in healthy controls. Ulcerative colitis patients also consumed more total protein than controls. The pathogenetic significance of these findings, however, remains unclear. ...

    PMID: 7866810, MUID: 95171184

    - Russ Johnson (Dallas, TX -- USA)

    Fri, 4 Jul 1997 1:02:45 GMT

    Two recently published papers provide solid evidence that Mycobacterium paratuberculosis is involved in at least a proportion of Crohn's disease. Crohn's disease is so similar to mycobacterial diseases that it is often confused with one of them, intestinal tuberculosis. Alan Kennedy maintains a very interesting web site on the subject: "Does Mycobacterium paratuberculosis cause Crohns disease?" -- a very thorough collection of material which suggest that Mycobacteria (paratubercolosis and avium) could be a possible cause of IBD.


    (In 1991, the Department of Medical Microbiology, Bartholomew's Hospital, London, came to the opposite conclusion, which you can read more about here.)

    Antioxidant defenses
    Wed, 4 June 1997 23:56:12 GMT

    Here is a new study that provides evidence that children with Crohn's disease have alterations in circulating antioxidant defenses, possibly related to an ongoing oxidant stress.

    Sun, 11 May 1997 13:35:33 GMT

    Hi SCD Group,

    Some news from the Danish Colitis-Crohn Associations magazine:

    The Danish Crohns-Colitis Association recently donated app. 11,000 US dollars for a research project which is to either confirm or kill the theory that there could be a relationship between the mycobacterium "Paratuberculosis" and Crohns.
    This mycobacteria can possibly affect the human immune-defense system, triggering the infection in the intestines. Since it is a bacteria that grows very slowly, it doesn't "show up" when our doctors and scientists look for it with the standard test methods.
    Two Danish doctors are going to join a professor from University of Wisconsin in Madison, USA, in researching, using a new DNA technology.

    Also, Danish scientists are presently looking into the effect of yoghurt "lactobacilles" which - if used in large quantity - can heal a wound in a week.


    Independent research supports SCD
    Fri, 2 May 1997 20:43:45 GMT

    New research from nutrional scientists here at the University of Illinois is published in the following papers:

    Campbell et al. 1997. An Enteral formula containing fish oil, indigestible oligosaccharides, gum arabic, and antioxidants affects plasma and colonic posphollipid fatty acid and prostaglandin profiles in pigs.
    Journal of Nutrition Science 127:137-145.

    Campbell et al. 1997. Selected indigestible oligosacharides affect large bowel mass, cecal and fecal short-chain fatty acids, ph and microflora in rats.
    Journal of Nutrition Science 127:130-136.

    These researchers found that commom simple-sugar molecules found in certian fruits and vegetables promote healthy intestinal function in part because they provide substrate for beneficial bacteria (bifidobacteria and lactobacilli) in the lower gut and create an increase of short-chain fatty acids (SCFAs) that have anti-inflamatory properties. They specifically note that these SCFAs "play a critical role in mucosal cell differentiation and, therefore integrity of the gastrointestinal mucosa" and "may be useful in promoting gastrointestinal health via restoration of normal flora following antibiotic therapy". Finally "...the data demonstrate that clinical studies utilizing human subject are warrented with the UCNF (ulcerative colitis nutritional formula) to further examine its impact on inflamatory responses in IBD patients".

    This is important stuff, folks - because this is controlled research done at a respected university by researchers with no knowledge of the scd (I spoke with one of them) that validates much of the scd approach. Something for the SCD-naysayers to think about!

    Hope I've brightened your day,
    Tim (Timothy R. Van Deelen)

    P.S. A third study is in the pipeline that says that artichokes, chickory, onions, garlic, leeks, shallots, chives, peaches, and bananas contain high levels of desireable oligosacharides.

    [Re: independent research supports SCD]
    Sat, 3 May 1997 7:11:55 GMT

    Yes, except the SCD explicitly excludes FOS - Fructo Oligiosacharides.

    - Harold

    A certain protein
    Sun, 27 Apr 1997 17:07:43 GMT

    To all:
    I have the opportunity to be involved in a study being done here in Edmonton, Alberta Canada at the university Hospital. I talked to the research nurse and in very short terms what it involves is this: The research team has found that people with Crohn's/colitis are lacking a certain protein and when this protein is injected back into the body ( much like diabetics do with insulin), the bowel actually heals. I realize this is an extremely simplified explanation but my appointment regarding this is tomorrow morning, so as soon as I have more info I will pass it along. Regardless of
    the outcome, I am going to stick with the diet as I truly believe it has the potential to heal just like this protein possibly does.

    Mon, 28 Apr 1997 18:01:14 GMT

    Hello everyone:
    I went for my appointment with the research nurse regarding participating in the treatment study for interleukin-10. She gave me an info sheet so I thought I'd pass it along.

    Interleukin-10 is a protein which normally circulates in the human body.

    All of the functions of Interleukin-10 have not yet been discovered.
    Indeed, Interleukin-10 was only discovered in1988 by a doctor who works at the University of Alberta. The main function of Interleukin-10 appears to be in helping control the body's immune system. In particular, interleukin-10 is important in reducing the amount of inflammation in your body and counteracting any stimulus that serves to increase inflammation.

    First, inflammatory bowel disease is a disease with increased inflammation.
    If interleukin-10 is capable of reducing this inflammation it may have a beneficial effect. Second, we have discovered that mice deficient in Interleukin-10 develop inflammatory bowel disease and when they are given Interleukin-10 the inflamatory bowel disease improves.

    Interleukin-10 is a protein which is destroyed by stomach acid and thus cannot be given by mouth. Interleukin-10 is therefore given by an injection identical to that used for insulin.

    Your white blood cell count may fall very slightly while you are receiving Interleukin-10 . This fallen white blood cell count will not cause you any
    problems. There are no other adverse effects of interleukin-10 that have been identified.

    Well, that's it. I'll know by next week whether or not I'll be participating, but I suppose it doesn't matter either way because I'm sticking with the diet but what's the harm in trying something that naturally occurs in the body anyways ( along with the diet) for an added benefit or to aid in the healing process.


    Re: Interleukin-10
    Mon, 28 Apr 1997 20:16:11 GMT

    Dear Allan and Martine,
    If you are on the SCD all the time, then how will they know whether it's the diet that's working or the interleukin-10?

    Re: Interleukin-10
    Tue, 29 Apr 1997 1:25:42 GMT

    Dear Anna,
    I have been on the diet for about 14 months, however the first seven months were without any medication and I made very little progress. Improvements since starting medication in September in conjunction with the SCD have been steady, but my quality of life is by no means where I would like it to be.
    A colonoscopy will be done prior to starting the Interleukin-10 treatment and one after. Therefore any major healing that takes place in that time was obviously mostly due to the Interleukin. BTW, I had a colonoscopy done about two months ago that showed quite extensive inflammation in the colon.
    As I mentioned earlier, I have no intention of going off of the SCD and feel that Interleukin-10, which naturally occurs in the body, can be of added benefit while sticking to the diet. After all, people take medications containing some forbidden substances ( i.e. Asacol has lactose) while on the diet and go into remission. So Interleukin, being totally legal on the SCD can do no harm and I think it's worth a chance. Ultimately, this study may benefit the countless number of people suffering from inflammatory bowel disease today.

    Dear Lorraine,
    Welcome to the group! I know you will find it to be very encouraging! It has been of immense help to me while following the diet religiously. You mentioned some interest regarding Interleukin-10. I think that it is quite exciting and if it can aid and perhaps speed up the healing process in conjunction with the diet, I am all for it. Approximately 300 patients at 35 multinational centers will be studied so if you are in Canada it might be worth a shot to discuss this with your specialist!
    Wishing you all the best on the SCD!

    Good health to you all!

    New drug
    Tue, 7 Jan 1997 19:35:34 GMT

    Thought you might be interested in this posting to the newgroup:

    >All of y'all should know about the IBD Home Page run by Dr. R. Holland
    >Please check it out at :
    >Many useful links and Ron has also astutely summarized much of the new
    >information and conference proceedings.

    There's info on encouraging results from use of heparin, an anticoagulant, for UC and Crohns.


    Tue, 17 Dec 1996 00:34:40
    Roger Easter writes:

    Those in UK maybe interested to know that Guys Hospital with Kings College Hospital in London are engaged in a research project looking at IBD in families. Both my brother and myself have UC. They reckon they are about 6 to 12 months away from discovering the rogue gene which they believe causes the problem.Stress being the trigger! Despite all the experts telling me that Stress does not cause it! It won't help provide a cure but at least we can do something about helping the family line in the future.
    If anybody on e,ail in UK is in this situ, i.e family with UC or Colitis etc please email me for further details.

    Roger Easter, Kenley Surrey

    back to start page

    This page updated on .